Semaglutide vs DSIP
A comprehensive, data-driven comparison of Semaglutide (Ozempic) and DSIP (Delta Sleep-Inducing Peptide). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Semaglutide Ozempic, Wegovy | DSIP Delta Sleep-Inducing Peptide |
|---|---|---|
| FDA Status | FDA Approved | Category 2 |
| Category | Weight Loss | Sleep |
| Primary Use | Type 2 diabetes, chronic weight management, and MASH | Sleep disorders and stress reduction |
| Weight Loss % | 15% | N/A |
| Monthly Cost | $1,000 - $1,400/mo | $35 - $70/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 2.4mg weekly (Wegovy dose) | 100-300mcg before bed |
| Frequency | Weekly | Daily |
| Mechanism | GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow gastric emptying, and reduce appetite | Neuropeptide that may modulate sleep patterns, reduce stress, and regulate circadian rhythms |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Emerging |
| Clinical Trial Phase | Approved | N/A |
Key Differences
- 1Semaglutide is FDA-approved, while DSIP is currently category 2.
- 2Semaglutide has clinical weight loss data (15%), while DSIP is not primarily indicated for weight loss.
- 3DSIP is generally more affordable ($35 - $70/mo) compared to Semaglutide ($1,000 - $1,400/mo).
- 4Semaglutide is dosed weekly, while DSIP is daily.
- 5Semaglutide has high-quality evidence, while DSIP has emerging-quality evidence.
- 6They belong to different categories: Semaglutide (Weight Loss) vs DSIP (Sleep).
Which Is Better For...
Semaglutide
Those seeking an FDA-approved treatment with established safety data
DSIP
More budget-friendly option with lower monthly costs
Semaglutide
More convenient dosing schedule (weekly)
DSIP
Fewer commonly reported side effects
Semaglutide
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Semaglutide | $1,000 - $1,400/mo | FDA Approved | Novo Nordisk |
| DSIP | $35 - $70/mo | Category 2 | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Semaglutide works via GLP-1 receptor agonist that mimics incretin hormone to increase insulin secretion, slow. DSIP works via Neuropeptide that may modulate sleep patterns, reduce stress, and regulate circadian rhythms. They differ in FDA approval status, efficacy data, and cost.
Semaglutide has demonstrated 15% average weight loss in clinical trials. DSIP is not primarily used for weight loss.
Semaglutide typically costs $1,000 - $1,400/mo, while DSIP costs $35 - $70/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Semaglutide is FDA-approved. DSIP is not FDA-approved (Category 2). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Semaglutide include Nausea, Diarrhea, Vomiting. Common side effects of DSIP include Injection site reactions, Drowsiness, Vivid dreams. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Semaglutide is an FDA-approved GLP-1 receptor agonist marketed as Ozempic for type 2 diabetes and Wegovy for chronic weight management. In August 2025, it received accelerated approval for MASH (metab...
View Full Semaglutide GuideDSIP (Delta Sleep-Inducing Peptide) is a neuropeptide first discovered in 1977 in the brains of sleeping rabbits. Research suggests it may have broader effects on stress response, pain modulation, and...
View Full DSIP GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Semaglutide and DSIP should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.